


OIPE  
 JUL 12 2004  
 37 CFR § 1.98(b)  
 PAT & TRADEMARK

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17541-005001	Application No. 09/503,559
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Roland Valdes Jr. et al.	
		Filing Date February 11, 2000	Group Art Unit 1648

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AH	GB 949 407	02/12/64	GB				
	AI							
	AJ							
	AK							
	AL							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
AW	AM	Qazzaz et al., "A commercially available standard for dihydroouabain has two chromatographically distinct biologically active components," <u>Clinical Chemistry</u> , 1997, 43:S191
	AN	Qazzaz et al., "Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues," <u>Archives of Biochemistry and Biophysics</u> , 1996, 328:193-200
	AO	El-Masri et al., "An antiserum for detection of a newly discovered dihydroouabain-like factor (Dihydro-OLF) isolated from mammals," <u>Clinical Chemistry</u> , 1999, 45:A82
	AP	Qazzaz et al., "A newly discovered lactone-hydrogenated isomer (Dihydro-OLF) of mammalian ouabain-like factor (OLF) differentially inhibits the sodium pump," <u>FASEB J.</u> , 1999, 13:A1470

Examiner Signature 	Date Considered 8/10/04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

<b>Complete If Known</b>	
Application Number	09/503559
Filing Date	February 11, 2000
First Named Inventor	Valdes, Jr., Roland
Group Art Unit	1617-1648
Examiner Name	Webman, Edward H. Winkler
Attorney Docket No: 1160.003US1	

Sheet 1 of 1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
--------------------	---------------------	------------------	---	-------	----------	----------------

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
W		QAZZAZ, HASSAN M., et al., "Secretion of a Lactone-Hydrogenated Ouabain-Like Effector of Sodium, Potassium-Adenosine Triphosphatase Activity by Adrenal Cells", <u>Endocrinology</u> , Vol. 141, No. 9, (2000), 3200-3209	
I		QAZZAZ, HASSAN M., et al., "Two Biologically Active Isomers of Dihydroouabain Isolated from a Commercial Preparation", <u>Biochimica et Biophysica Acta</u> 1472, (1999), 486-497	
B		ZHAO, NING, et al., "Na, K-ATPase Inhibitors from Bovine Hypothalamus and Human Plasma are Different from Ouabain: Nanogram Scale CD Structural Analysis", <u>Biochemistry</u> , Vol. 34, No. 31, (1995), 9893-9896	

RECEIVED  
APR 14 2003  
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

6/23/03



SEP 07 2000  
TECH CENTER 1600/2000

RECEIVED  
SEP 07 2000

TECH CENTER 1600/2000

Sheet 1 of 1

Form 1449\*

Atty. Docket No.: 1160.003US1

Serial No. 09/503,559

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant: Roland Valdes, Jr. et al.

Filing Date: February 11, 2000

Group: ~~1614~~ 1648

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
						If Appropriate
<u>W</u>	5,429,928	07/04/1995	Blaustein et al.	435	7.24	07/28/92
<u>W</u>	5,695,756	12/09/1997	Blaustein et al.	424	130.1	06/06/95
<u>W</u>	5,844,091	12/01/1998	Blaustein et al.	530	387.1	06/25/93

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
<u>W</u>	Qazzaz, et al., "Isolation of two chromatographically and biologically distinct components from a dihydroouabain commercial preparation", <u>EASEB J.</u> , 11(9), Abstract 1423, page A1100 (1997).

Examiner

Date Considered

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.